Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved Targretin er større end risiciene ved behandling af hudmanifestationer hos patienter med kutant T- celle- lymfom på et fremskredet stadium, der er resistente over for mindst én systemisk behandlingsform.
The Committee for Medicinal products for Human Use (CHMP) decided that Targretin’ s benefits are greater than its risks for the treatment of the skin manifestations of advanced stage cutaneous T-cell lymphoma patients refractory to at least one systemic treatment.